Is terbinafine an appropriate treatment for frontal fibrosing alopecia?

Terbinafine is NOT an appropriate treatment for frontal fibrosing alopecia

Terbinafine has no established role in the treatment of frontal fibrosing alopecia (FFA) and should not be used for this condition. The FDA-approved indication for oral terbinafine is exclusively for fungal infections of the fingernails and toenails (onychomycosis) 1. FFA is a primary lymphocytic cicatricial (scarring) alopecia, not a fungal infection, making terbinafine mechanistically inappropriate.

Why Terbinafine Does Not Work for FFA

The pathophysiology of FFA involves:

• Loss of follicular immune privilege in the bulge region
• Lymphocytic inflammation targeting hair follicle stem cells
• Epithelial-mesenchymal transition leading to irreversible scarring and follicular deletion 2

Terbinafine is an antifungal agent that inhibits fungal squalene epoxidase. It has no anti-inflammatory, immunomodulatory, or anti-androgenic properties that would address the underlying mechanisms of FFA.

Evidence-Based Treatment Options for FFA

The most recent consensus and review data support the following approach 3:

First-line multimodal therapy should include:

• Oral dutasteride (5α-reductase inhibitor) - 88% response rate in published series 4
• Intralesional triamcinolone acetonide - 88% response rate (181/204 patients) 4
• Hydroxychloroquine if inflammation persists - statistically significant reduction in signs/symptoms at 6 and 12 months 5

Treatment Algorithm

1. Start immediately with combination therapy (hair loss is irreversible):

   • Oral dutasteride 0.5 mg daily
   • Intralesional triamcinolone acetonide (5-10 mg/mL) monthly to affected areas

2. Add hydroxychloroquine if scalp pruritus, perifollicular erythema, or other inflammatory signs persist after 2-3 months 3

3. Consider adding (if inadequate response):

   • Topical calcineurin inhibitors
   • Oral isotretinoin (particularly effective for facial papules; ~90% symptom reduction) 6
   • JAK inhibitors like tofacitinib in refractory cases 7

Critical Clinical Pearls

Early intervention is essential - FFA causes permanent follicular destruction, so treatment aims to arrest progression rather than restore lost hair 4, 8. The maximal benefit from hydroxychloroquine occurs within the first 6 months 5.

Common presenting features to recognize:

• Progressive frontotemporal hairline recession (100%)
• Eyebrow loss (75%)
• Scalp pruritus (67%)
• Perifollicular erythema (86%)
• Predominantly affects postmenopausal women (83%) 5, 9

Avoid monotherapy - The Spanish consensus emphasizes multimodal therapy with complementary mechanisms from the outset because of the irreversible nature of scarring 3.

The provided evidence includes guidelines for alopecia areata 10, which is a completely different non-scarring autoimmune condition. These guidelines are not applicable to FFA and should not guide treatment decisions for this distinct disease entity.